Literature DB >> 3258991

Tissue localization and fate in mice of injected multipotential colony-stimulating factor.

D Metcalf1, N A Nicola.   

Abstract

The hemopoietic regulator multipotential colony-stimulating factor [Multi-CSF (interleukin 3)] has proliferative effects on a wide range of hemopoietic cells in vitro and in vivo. Native or recombinant Multi-CSF injected intravenously into adult mice had an initial half-life of 3-5 min and a second phase of 50 min. Clear labeling of hemopoietic cells was observed in the bone marrow and spleen of mice injected intravenously with recombinant 125I-labeled Multi-CSF showing that injected Multi-CSF can obtain access to such cells in situ. A high proportion of injected 125I-labeled Multi-CSF of both types became localized in the liver and in the kidney (in cells of the Bowman's capsule and proximal renal tubules). The kidney appeared to be an active site of degradation of Multi-CSF with the early appearance of low molecular weight labeled material in the urine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3258991      PMCID: PMC280163          DOI: 10.1073/pnas.85.9.3160

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  15 in total

1.  Physiologic distribution of colony-stimulating factor in vivo.

Authors:  R K Shadduck; A Waheed; A Porcellini; V Rizzoli; G Pigoli
Journal:  Blood       Date:  1979-10       Impact factor: 22.113

2.  Molecular cloning of cDNA for murine interleukin-3.

Authors:  M C Fung; A J Hapel; S Ymer; D R Cohen; R M Johnson; H D Campbell; I G Young
Journal:  Nature       Date:  1984 Jan 19-25       Impact factor: 49.962

3.  Characterization and partial purification of a haemopoietic cell growth factor in WEHI-3 cell conditioned medium.

Authors:  G W Bazill; M Haynes; J Garland; T M Dexter
Journal:  Biochem J       Date:  1983-03-15       Impact factor: 3.857

4.  Molecularly cloned and expressed murine T-cell gene product is biologically similar to interleukin-3.

Authors:  J S Greenberger; R K Humphries; H Messner; D M Reid; M A Sakakeeny
Journal:  Exp Hematol       Date:  1985-05       Impact factor: 3.084

5.  The in vivo functions and properties of persisting cell-stimulating factor.

Authors:  R M Crapper; I Clark-Lewis; J W Schrader
Journal:  Immunology       Date:  1984-09       Impact factor: 7.397

6.  Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity.

Authors:  J N Ihle; J Keller; S Oroszlan; L E Henderson; T D Copeland; F Fitch; M B Prystowsky; E Goldwasser; J W Schrader; E Palaszynski; M Dy; B Lebel
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

7.  Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth.

Authors:  M A Cheever; J A Thompson; D E Kern; P D Greenberg
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

8.  Biologic properties of molecularly cloned and expressed murine interleukin-3.

Authors:  A J Hapel; M C Fung; R M Johnson; I G Young; G Johnson; D Metcalf
Journal:  Blood       Date:  1985-06       Impact factor: 22.113

9.  Quantitative responsiveness of murine hemopoietic populations in vitro and in vivo to recombinant multi-CSF (IL-3).

Authors:  D Metcalf; C G Begley; N A Nicola; G R Johnson
Journal:  Exp Hematol       Date:  1987-03       Impact factor: 3.084

10.  Studies on the in vivo production of a lymphokine activity, interleukin 3 (IL-3) elaborated by lymphocytes and a myeloid leukaemic line in vitro and the fate of IL-3 dependent cell lines.

Authors:  J M Garland; A Aldridge; J Wagstaffe; T M Dexter
Journal:  Br J Cancer       Date:  1983-08       Impact factor: 7.640

View more
  3 in total

Review 1.  Why clinicians should be interested in interleukin-3.

Authors:  P Valent; K Geissler; C Sillaber; K Lechner; P Bettelheim
Journal:  Blut       Date:  1990-12

Review 2.  Interleukins. Clinical pharmacokinetics and practical implications.

Authors:  V Bocci
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

3.  Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5.

Authors:  L Robb; C C Drinkwater; D Metcalf; R Li; F Köntgen; N A Nicola; C G Begley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.